New England Journal of Medicine 2021
Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis
NEJM 2021; 385:2441-2450
Pulmonary Arterial Hypertension (Review article)
NEJM 2021; 385:2361-2376
Latent Tuberculosis Infection (Clinical practice)
NEJM 2021; 385:2271-2280
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
NEJM 2021; 385:2230-2240
Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial
NEJM 2021; 385:1669-1679
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
NEJM 2021; 385:1656-1668
Review Article: Perspectives on the Treatment of Malignant Pleural Mesothelioma
N Engl J Med 2021; 385:1207-1218
Acquired Resistance to KRAS
G12C Inhibition in Cancer
N Engl J Med 2021; 384:2382-2393
Sotorasib for Lung Cancers with
KRAS p.G12C Mutation
N Engl J Med 2021; 384:2371-2381
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
N Engl J Med 2021; 384:1800-1809
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis N Engl J Med 2021; 384:1705-1718
